Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV)

Latest Posts

Studies: RSV prevention strategies—especially nirsevimab—may cut infant hospitalizations​
RSV confers similar risk of poor outcomes in hospitalized patients as flu over time, data suggest​
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids​
RSV vaccine protects older adults, and drug protects babies, but less so over time, studies suggest​
Recently approved RSV prevention therapies may be next FDA target​
RSV tied to heart problems, breathing issues well after infection in adults​
RSV vaccine highly effective against hospital admission in older adults, study suggests​
Nirsevimab prevents RSV cases in young kids for 1 year but maybe not beyond, data suggest​
HEPA purifiers not tied to less viral exposure in elementary classrooms, analysis finds​
Data: Pediatric hospital strain amid 2022-23 respiratory virus season not tied to decline in beds​
Only 6 symptoms, conditions appear unique to long COVID, suggesting overlap with other post-viral infections​
RSV tied to high complication, death rates in hospitalized older adults​
Quick takes: Re-emergent COVID strain, extended US RSV season, typhus in California​
CDC data suggest flu is on the way out​
RSV vaccination coverage remains low among older US adults​
CDC reports 14 more pediatric flu deaths, 115 total​
FDA approves use of RSV vaccine in at-risk younger adults​
CDC reports 11 more pediatric flu deaths​
Medical societies recommend RSV vaccines for older or immune-compromised adults​
Up to 56,000 people died from COVID-19 or RSV last year​